Ondine's Periowave(TM) Product approved for Additional Indications in European Union

    - Peri-implantitis and Endodontic Applications -

    VANCOUVER, June 28 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM:
OBP) today announced that the European Commission has approved its
Periowave(TM) Photodisinfection System for the treatment of dental
peri-implant disease as well as for endodontic disinfection. The European
Commission decision applies to all 27 countries in the European Union as well
as Iceland and Norway. These additional indications build upon the previously
approved Periowave(TM) indication for the treatment of periodontal disease. In
addition to the European Union, Periowave(TM) is currently approved and
marketed in Canada.
    "We are pleased to be able to report on the review and approval by
European regulatory authorities of these expanded indications," stated Carolyn
Cross, President and CEO of Ondine. "European dental practitioners are now
equipped with a novel, alternative therapeutic option in the treatment of the
complex, polymicrobial infections that often characterize intra-oral diseases
such as peri-implantitis and periodontitis. Over time, our goal is to provide
the dental clinic with the leading, one-stop disinfection technology to
satisfy all therapeutic and prophylactic disinfection requirements. Meanwhile
in the US, we expect to submit our application shortly for the gum disease
indication to the FDA, building upon our extensive experience with
Periowave(TM) and the numerous satisfied practitioners and patients."

    About Peri-Implant Disease and Endodontics

    Peri-implantitis affects 5% to 10% of implant patients and is a form of
gum disease caused by bacteria that colonize the tissues surrounding a dental
implant. If left untreated, peri-implantitis may lead to loss of the bone
structure supporting an implant, a major cause of implant failure. Endodontics
is a branch of dentistry concerned with the treatment of the pulp chamber, or
root canal, of the tooth. This chamber contains nerves, blood vessels and
cells regulating tooth development. Pulp decay is caused by a bacterial
invasion of the pulp chamber. If left untreated, this infection may spread
from the pulp chamber to tissues surrounding the root, causing further
breakdown and severe pain.

    About Periowave(TM) and Photodisinfection

    Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
compounds to specifically target and destroy microbial pathogens and reduce
the symptoms of disease. The compounds are generally topically applied and one
or more lasers are used to activate the compounds and complete the

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading-edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance.
    The Company is headquartered in Vancouver, British Columbia, Canada, with
a research laboratory in Bothell, Washington, USA, and an international office
in St. Michael, Barbados. For additional information, please visit the
Company's website at: www.ondinebiopharma.com.

    Forward-Looking Statements:

    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release

For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890